Pharmaceutical

J&J seeks label expansion for Tremfya in ulcerative colitis

Johnson & Johnson’s Tremfya is approved for plaque psoriasis and active psoriatic arthritis, with a label for ulcerative colitis now on the horizon.

Mar 13, 2024 - 00:00
J&J seeks label expansion for Tremfya in ulcerative colitis
Johnson & Johnson’s Tremfya is approved for plaque psoriasis and active psoriatic arthritis, with a label for ulcerative colitis now on the horizon.
Read the original article

Tags:

Previous Article

Jaguar Health balances ambitions for human and animal pharmaceuticals

Next Article

Tierra raises $11.4 in Series A round for predictive AI protein maker

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bavarian Nordic seeks authorisation for mpox vaccine’s use in adolescents

Bavarian Nordic seeks authorisation for mpox vaccine’s ...

Aug 17, 2024

STAT+: Cambridge announced as ‘investor catalyst’ hub for ARPA-H

STAT+: Cambridge announced as ‘investor catalyst’ hub f...

Sep 26, 2023

STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs

STAT+: Pharmalittle: CRISPR pioneers reflect on future ...

Nov 21, 2023